Therachon AG
About Therachon AG
Therachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. We are committed to the community, caregivers and advancing research to transform the lives of people with unmet medical needs. We are deeply committed to fostering a community that is rigorous about science and passionate about making a difference by translating the promise of our science into new treatments for patients.YEAR FOUNDED:
2014
LEADERSHIP:
Founder: Elvire Gouze
CEO: Luca Santarelli
COO: Richard Porter
FOLLOW THERACHON:
Tweets by Therachon
14 articles about Therachon AG
-
Pfizer Completes Acquisition of Therachon
7/1/2019
Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio
-
Therachon to Present Data from Ongoing Phase II Study of Apraglutide for Short Bowel Syndrome (SBS) at Digestive Disease Week
5/17/2019
Therachon AG ("Therachon"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions, today announced that it will present interim results from its ongoing Phase II clinical study of apraglutide at Digestive Disease Week® (DDW) in San Diego, CA.
-
Pfizer Acquires Clinical-Stage Biotech Therachon
5/8/2019
Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism
-
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
-
Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
3/25/2019
Results establish favorable safety profile and show the potential for efficacy with once-weekly dosing of a next generation GLP-2 analog
-
Therachon is granted Orphan Drug Designation in the European Union for Apraglutide for the Treatment of Short Bowel Syndrome
11/29/2018
Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation for apraglutide for the treatment of short bowel syndrome (SBS). "
-
Therachon Expands Rare Disease Pipeline with Acquisition of GLyPharma Therapeutic Inc.
10/9/2018
Transformational acquisition advances Therachon's mission to develop best-in-disease therapies
-
Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline
8/9/2018
Jørgen Søberg Petersen, M.D., Ph.D., DMSc, MBA and Timothy Anderson to Join Board of Directors
-
Therachon Announces Dosing of First Subject in Phase I Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
2/14/2018
Therachon today announced the dosing of the first subject in its Phase 1 trial for TA-46, a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) ligand trap.
-
Therachon Appoints Biotechnology Leader Christian Meyer, M.D., Ph.D., As Chief Medical Officer
8/29/2017
-
Therachon Receives EMA And FDA Orphan Drug Designation For TA-46 For Achondroplasia
6/20/2017
-
Therachon Appoints Dr. Maarten Kraan, Ph.D., M.D., Chief Medical Officer
3/21/2017
-
Therachon Supports Rare Disease Day And Joins Global Movement To Raise Important Awareness For Rare Diseases
2/28/2017
-
Therachon Appoints Industry Leaders To Board Of Directors, Top Management Roles
2/15/2017